Tokyo Tape
Sign in
← Koa Shoji Holdings

Quarterly report · Q2

9273.TEDINET S100SVUE
Period2023-07-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥11.4bn2023-07-01 → 2023-12-31Cons.Net sales
Revenue¥22.1bn2022-07-01 → 2023-06-30Cons.Net sales (5-year summary)
Revenue¥11.2bn2022-07-01 → 2022-12-31Cons.Net sales
Operating income¥2.4bn2023-07-01 → 2023-12-31Cons.Operating income
Operating income¥2.2bn2022-07-01 → 2022-12-31Cons.Operating income
Ordinary income¥2.4bn2023-07-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥4.1bn2022-07-01 → 2023-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.2bn2022-07-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥2.4bn2023-07-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥2.2bn2022-07-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥1.6bn2023-07-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.7bn2022-07-01 → 2023-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.4bn2022-07-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥1.6bn2023-07-01 → 2023-12-31Cons.Profit loss
Net income¥1.4bn2022-07-01 → 2022-12-31Cons.Profit loss
Total assets¥29.6bnat 2023-12-31Cons.Assets
Total assets¥28.5bnat 2023-06-30Cons.Assets
Total assets¥27.6bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥7.7bnat 2023-12-31Cons.Liabilities
Total liabilities¥7.5bnat 2023-06-30Cons.Liabilities
Net assets / equity¥22.0bnat 2023-12-31Cons.Net assets
Net assets / equity¥20.9bnat 2023-06-30Cons.Net assets
Net assets / equity¥19.6bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥11.0bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥10.8bnat 2023-06-30Cons.Cash and deposits
Cash & equivalents¥10.3bnat 2023-12-31Cons.Cash and cash equivalents
Cash & equivalents¥10.0bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥8.2bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥8.4bnat 2022-06-30dCons.Cash and cash equivalents
Operating cash flow¥1.5bn2023-07-01 → 2023-12-31Cons.Net cash provided by used in operating activities
Operating cash flow¥2.7bn2022-07-01 → 2023-06-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥518m2022-07-01 → 2022-12-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥644m2023-07-01 → 2023-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥304m2022-07-01 → 2023-06-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥120m2022-07-01 → 2022-12-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥639m2023-07-01 → 2023-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥812m2022-07-01 → 2023-06-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥600m2022-07-01 → 2022-12-31Cons.Net cash provided by used in financing activities
EPS (basic)¥39.462023-07-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥20.342023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥67.832022-07-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥35.192022-07-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥19.92022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio74.2%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio73.5%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio70.8%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-07-01 → 2023-12-31−¥871m
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2023-12-31−¥871m
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2023-12-31−¥38m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2023-07-01 → 2023-12-31¥7.9bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2023-07-01 → 2023-12-31¥7.0bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2023-07-01 → 2023-12-31¥871m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2023-07-01 → 2023-12-31¥1.4bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2023-07-01 → 2023-12-31¥4.4bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2023-07-01 → 2023-12-31¥4.4bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2023-07-01 → 2023-12-31¥1.0bn
—segment totalrevenue2023-07-01 → 2023-12-31¥12.3bn
—segment totalrevenue external2023-07-01 → 2023-12-31¥11.4bn
—segment totalrevenue intersegment2023-07-01 → 2023-12-31¥871m
—segment totalsegment profit2023-07-01 → 2023-12-31¥2.4bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-12-31−¥925m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-12-31−¥925m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-12-31¥22m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2022-07-01 → 2022-12-31¥8.1bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2022-07-01 → 2022-12-31¥7.2bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2022-07-01 → 2022-12-31¥925m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2022-07-01 → 2022-12-31¥1.4bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2022-07-01 → 2022-12-31¥4.0bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2022-07-01 → 2022-12-31¥4.0bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2022-07-01 → 2022-12-31¥761m
—segment totalrevenue2022-07-01 → 2022-12-31¥12.1bn
—segment totalrevenue external2022-07-01 → 2022-12-31¥11.2bn
—segment totalrevenue intersegment2022-07-01 → 2022-12-31¥925m
—segment totalsegment profit2022-07-01 → 2022-12-31¥2.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 493
ItemContextValueUnit
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-924850000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember8097264000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember3994560000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember12091824000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-924850000JPY
Net salesPrior1YTDDuration11166974000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember1376943000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember761038000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember2137981000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember22259000JPY
Operating incomePrior1YTDDuration2160241000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember7010357000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember4372585000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember11382942000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration11382942000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember870846000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember870846000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-870846000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember7881203000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember4372585000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember12253788000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-870846000JPY
Net salesCurrentYTDDuration11382942000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember1399335000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember1031539000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember2430874000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember-37573000JPY
Operating incomeCurrentYTDDuration2393300000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-02-14
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第10期第２四半期（自　2023年10月１日　至　2023年12月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)コーア商事ホールディングス株式会社
Company name in english cover pageFilingDateInstantKOA SHOJI HOLDINGS CO.,LTD.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　首藤　利幸
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)神奈川県横浜市港北区日吉七丁目13番15号
Telephone number address of registered headquarter cover pageFilingDateInstant045-560-6607
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役　　小松　美代子
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)神奈川県横浜市港北区日吉七丁目13番15号
Telephone number nearest place of contact cover pageFilingDateInstant045-560-6607
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役　　小松　美代子
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE34071
Fund codeFilingDateInstant－
Security codeFilingDateInstant92730

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-06-30pass rounding
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-07-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-07-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-07-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-07-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass